As Russia prepares to implement a controversial new rule in its state drug procurement system, patients and healthcare advocates alike are bracing for significant changes. The policy, dubbed “Second One Out,” aims to bolster domestic pharmaceutical production, but its potential side effects could leave citizens facing fewer choices and higher costs for vital medications.
The New Mandate: National Priority
Starting in September, a new directive will reshape how Russia acquires its essential medicines for public use. The “Second One Out” rule dictates that domestic pharmaceutical products will receive preferential treatment in state tenders. This means if a Russian-made analogue exists and a local manufacturer bids for the contract, foreign competitors, regardless of their superior efficacy or more competitive pricing, will effectively be excluded. This stringent approach is set to impact a staggering 215 strategically important drugs, including critical oncology treatments, narcotics, psychotropic medications, and blood products.
This isn`t Russia`s first foray into such protectionist measures. According to Alexander Saversky, head of the All-Russian Public Organization “League for Patient Protection,” similar policies have been quietly in effect since January 2025 for a list of vital and essential medicines (the so-called “third one out” rule). The upcoming shift merely expands the scope, bringing a wider array of life-saving drugs under this new, tightened regime.
Sovereignty at a Cost?
The rationale behind this policy is clear: national sovereignty and self-sufficiency in a critical sector. Proponents argue that relying on domestic production strengthens the nation`s independence and economic resilience. However, Mr. Saversky offers a more nuanced, and perhaps ironic, perspective. He points out that while the idea of self-reliance is commendable, it seemingly overlooks the fundamental purpose of medication: human health.
Indeed, a curious loophole exists: if a foreign drug is merely *packaged* within Russia, it can be classified as a domestic product. While this offers a slim window for some international pharmaceuticals to remain in the market, it hardly addresses the core issue of potential quality or availability disparities. The grim reality, as Saversky notes, is that 150 to 250 drugs already vanish from the State Register of Medicines annually, often due to these very administrative hurdles.
The Patient`s Predicament: Choice and Trust
Perhaps the most poignant aspect of this policy is its impact on the very individuals it`s meant to serve: patients. Unlike car parts, human bodies and their illnesses do not readily conform to bureaucratic mandates. Patients, particularly those with chronic or life-threatening conditions, often rely on specific medications that have proven effective for them over years.
A diabetic, for instance, whose insulin regimen has been carefully calibrated over several years, faces the daunting prospect of forced changes every few months. Oncology patients, who place immense trust in the efficacy of their current treatments, may find themselves compelled to switch to unfamiliar alternatives. The emotional and physical toll of such transitions can be substantial, potentially undermining the stability of their health management.
A key missing piece, according to Saversky, is the absence of a legal framework for patients to provide informed consent regarding their prescribed medications. Unlike other medical interventions, doctors in Russia typically do not seek explicit patient agreement for drug choices. This absence of patient agency, he argues, directly contradicts the principle of freedom of competition, where consumer choice is paramount. It creates a system where the state procures what it deems necessary, rather than what the patient requires or prefers.
A Costly “Benefit”: When Subsidies Go Unused
The policy`s administrative elegance might appeal to budget planners, but its real-world application reveals a surprising inefficiency. Rather than ensuring affordable access, the “Second One Out” rule may inadvertently lead to wasted public funds. Saversky highlights survey data showing that a significant portion of patients—between 45% and 60%—prefer to purchase their preferred medications from other manufacturers, despite being eligible for state-subsidized alternatives.
This phenomenon represents a quiet but potent form of patient protest. If individuals are willing to spend their own money to secure the drugs they trust, it signals a fundamental disconnect between state procurement policies and actual patient needs. The government, in its diligent effort to provide “cheaper” medicines, may inadvertently be acquiring products that a large segment of the population either cannot, or will not, use. The result is a paradox: a policy intended to save money and promote self-reliance ends up contributing to inefficiencies and leaving patients to bear the financial burden of their own healthcare choices.
Looking Ahead: The Human Equation
As September approaches, the true implications of Russia`s “Second One Out” rule will unfold. While the drive for national pharmaceutical independence is understandable in the current global climate, the success of such a policy ultimately hinges on its ability to serve the public good without compromising health outcomes. The ongoing challenge for policymakers will be to reconcile the pursuit of sovereignty with the fundamental needs and autonomy of individual patients, ensuring that state-driven initiatives truly enhance, rather than inadvertently hinder, the well-being of the population.
